Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines

Phase 3

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: LOU064 (blinded)
Drug: Placebo
Drug: LOU064 (open-label)

First Posted Date: 2021-09-02

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 455

Registration Number: NCT05032157

Locations: 🇺🇸
Cahaba Derm and skin hlth ctr 27, Birmingham, Alabama, United States
🇺🇸
Research Solutions of Arizona, Litchfield Park, Arizona, United States
🇺🇸
Little Rock Allergy and Asthma Clnc, Little Rock, Arkansas, United States

and more 28 locations

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines

Phase 3

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: Placebo
Drug: LOU064 25 mg (b.i.d)
Drug: LOU064 25 mg (b.i.d) as a tablet.

First Posted Date: 2021-09-01

Last Posted Date: 2024-12-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 470

Registration Number: NCT05030311

Locations: 🇹🇷
Novartis Investigative Site, Talas Kayseri, Turkey
🇺🇸
Finlay Medical Research, Greenacres City, Florida, United States

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Phase 3

Active, not recruiting

Conditions: Atherosclerotic Cardiovascular Disease

Interventions: Drug: Inclisiran sodium 300 mg
Drug: Placebo

First Posted Date: 2021-09-01

Last Posted Date: 2024-12-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 17004

Registration Number: NCT05030428

Locations: 🇺🇸
CCT Research, Omaha, Nebraska, United States
🇺🇸
Pima Heart And Vascular Clin Rch, Tucson, Arizona, United States
🇺🇸
ARcare Center for Clinical Research, Little Rock, Arkansas, United States

and more 264 locations

Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Pelacarsen

First Posted Date: 2021-08-30

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 17

Registration Number: NCT05026996

Locations: 🇺🇸
Novartis Investigative Site, San Antonio, Texas, United States

Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines

Phase 3

Terminated

Conditions: Chronic Inducible Urticaria

Interventions: Drug: Ligelizumab
Other: Placebo

First Posted Date: 2021-08-27

Last Posted Date: 2024-06-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 39

Registration Number: NCT05024058

Locations: 🇹🇷
Novartis Investigative Site, Istanbul, Turkey

Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world

Recruiting

Conditions: Breast Cancer

Interventions: Other: alpelisib plus fulvestrant

First Posted Date: 2021-08-26

Last Posted Date: 2024-07-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 200

Registration Number: NCT05022342

Locations: 🇮🇳
Novartis Investigative Site, Kolkata, India

Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India

Terminated

Conditions: Sickle Cell Disease

Interventions: Other: Crizanlizumab

First Posted Date: 2021-08-25

Last Posted Date: 2024-06-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 44

Registration Number: NCT05020873

Locations: 🇸🇦
Novartis Investigative Site, Jazan, Saudi Arabia

Pharmacokinetics Study of FIA586 in Participants With Mild and Moderate Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: FIA586

First Posted Date: 2021-08-06

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT04993157

Locations: 🇺🇸
Novartis Investigative Site, Orlando, Florida, United States

A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD)

Phase 2

Terminated

Conditions: Mixed Connective Tissue Disease
Sjogren Syndrome

Interventions: Drug: Placebo
Drug: MHV370

First Posted Date: 2021-08-03

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT04988087

Locations: 🇨🇳
Novartis Investigative Site, Kaohsiung, Taiwan

Regulatory Post-Marketing Surveillance Study for Brolucizumab

Recruiting

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Other: brolucizumab

First Posted Date: 2021-08-02

Last Posted Date: 2024-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3000

Registration Number: NCT04985487

Locations: 🇰🇷
Novartis Investigative Site, Taegu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy